07:06 EST Insmed (INSM) sees FY26 global Arikayce revenue $450M-$470M
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target lowered to $157 from $158 at Morgan Stanley
- Insmed price target lowered to $215 from $223 at UBS
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials
- Insmed assumed with a Buy at Truist
- Insmed: Brinsupri-Led Growth, Pipeline Optionality, and Discounted Valuation Underpin Buy Rating